Healthcare News

Approval is based on Phase 3 results demonstrating significant progression-free and overall survival benefits, with teclistamab reducing risk of disease progression or death by 71% and risk of death...

BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- A 9-year-old boy has become the world's first patient to receive a newly approved implant to treat congenital nystagmus, in a procedure performed at Peking...

PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the...

RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- What began with a single cardiac catheterization laboratory four decades ago has evolved into an advanced cardiovascular program at King...

HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratoryHQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near...

PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial...

82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib  ...

Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and...

EssilorLuxottica announces S&P Global’s rating upgrade to A+ Paris, France (October 23, 2026) – EssilorLuxottica announces today that S&P Global Ratings has upgraded the Group’s long-term...

EssilorLuxottica annonce le relèvement à A+ de sa note S&P Global Ratings Paris, France (23 octobre 2026) – EssilorLuxottica annonce aujourd'hui que la note de crédit à long terme S&P Global...